Zacks.com on MSN1h
BridgeBio Stock Up on FDA Approval of Cardiovascular DrugBridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...
We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
Scotiabank has recently initiated BridgeBio Pharma Inc (BBIO) stock to Sector Outperform rating, as announced on October 16, 2024, according to Finviz. Earlier, on October 3, 2024, Oppenheimer had ...
Investor's Business Daily on MSN20h
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart DrugBridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, ...
In a report released today, Cory Kasimov from Evercore ISI reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
Oppenheimer analyst Trevor Allred maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares opened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback